Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Radiopharm Theranostics Limited ( (AU:RAD) ) has shared an announcement.
Radiopharm Theranostics has disclosed a change in the interests of director Ian Turner, detailing adjustments to his direct and indirect holdings in the company’s shares and options. The filing indicates the expiry of a tranche of unlisted options and an on-market acquisition of additional fully paid ordinary shares, resulting in a higher total shareholding but a reduced options position for the director.
The updated holdings show Turner now controls nearly 10 million shares and just under 24 million options across direct and superannuation-related interests. These changes, reported under ASX listing requirements, refine the transparency around insider ownership, which is closely watched by investors as a signal of management’s alignment with shareholder interests and confidence in the company’s future prospects.
The most recent analyst rating on (AU:RAD) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited (ASX: RAD) is an Australia-listed company operating in the medical and biotechnology sector, focusing on radiopharmaceuticals and theranostic solutions. The company develops and commercialises targeted diagnostic and therapeutic products that use radioactive compounds to detect and treat diseases, positioning itself within the emerging field of precision nuclear medicine.
Average Trading Volume: 3,791,136
Technical Sentiment Signal: Sell
Current Market Cap: A$70.88M
For an in-depth examination of RAD stock, go to TipRanks’ Overview page.